id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-276808-sax7qc85	Rosas, I.	Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia	2020-09-01		.txt	text/plain	4987	322	48	CONCLUSIONS In this randomized placebo-controlled trial in hospitalized COVID-19 pneumonia patients, tocilizumab did not improve clinical status or mortality. . https://doi.org/10.1101/2020.08.27.20183442 doi: medRxiv preprint This is the first global, randomized, double-blind, placebo-controlled trial to investigate whether tocilizumab has clinical benefit in hospitalized patients with severe COVID-19 pneumonia. The ratio of the odds of being in a better clinical status category for tocilizumab versus placebo was determined using a proportional odds model to give odds ratios and 95% CIs. Data from the last available postbaseline assessment on the ordinal scale were used for patients who withdrew before day 28, and all deaths and hospital discharges were carried forward. Among treatments for patients hospitalized with COVID-19 investigated in randomized controlled trials, dexamethasone reduced mortality in patients receiving is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint	./cache/cord-276808-sax7qc85.txt	./txt/cord-276808-sax7qc85.txt